Potential and prospects of biomass as a source of renewable energy in Pakistan

In an agricultural country like Pakistan, producing affordable and clean energy can be a challenging task. However, Pakistan has the potential to utilize various biomass feedstocks to generate renewable energy and tackle climate change while promoting sustainable development. Wheat, rice, sugarcane, and corn are the four main crops that yield a significant amount of residue, totaling 112.1 million tons per year. These residues have the potential to produce 3,050 kWh/ton of energy, which can meet 14% of the energy demand in Pakistan, equivalent to 9.85TW, starting in 2022. Gasification technology is a versatile option that efficiently converts biomass into energy while reducing negative environmental impacts. The current research explores the feasibility of generating clean energy from crop residues with low emissions, addressing the country’s energy needs, and supporting policymakers in promoting the use of biomass for energy production. According to this study, rice husk, corn cobs, wheat straw, and sugar bagasse all produce hydrogen at rates of 6.9 wt.%, 6.4 wt.%, 5.69 wt.%, and 5.35 wt.%, respectively. Therefore, our study demonstrates that corn cobs have a significant potential for energy production

Clinical trials landscape in a lower-middle-income country (Pakistan)

In recent times, there have been calls from within the developing nations for increased ownership by governmental research bodies and universities of the priority research setting and research that aligns with national health strategies. This is a review paper of the studies that have been published on clinical trials in developing countries, with a focus mainly on Pakistan. The literature review used online databases such as PubMed, Scopus, and Google Scholar, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov trial registries to search for clinical trials conducted in Pakistan between January 2000 and December 2022 and analyzed. The results revealed that clinical research in Pakistan is hindered by a number of barriers, including a lack of funding, skilled personnel, and regulatory issues. Lack of funding is a common obstacle, and the majority of funding for clinical trials originates from Western countries or pharmaceutical companies established in the West. In conclusion, clinical studies in developing countries, especially in Pakistan, are hindered by a plethora of barriers, and to improve the current state, increasing funding, streamlining ethical approval procedures, simplifying regulatory systems, addressing cultural and religious concerns, and participating in global efforts to bridge the gap in health-based research are crucial